Loading…
VEGFR-3 signaling in macrophages: friend or foe in disease?
Lymphatic vessels have been increasingly appreciated in the context of immunology not only as passive conduits for immune and cancer cell transport but also as key in local tissue immunomodulation. Targeting lymphatic vessel growth and potential immune regulation often takes advantage of vascular en...
Saved in:
Published in: | Frontiers in immunology 2024, Vol.15, p.1349500 |
---|---|
Main Authors: | , |
Format: | Article |
Language: | English |
Subjects: | |
Citations: | Items that this one cites |
Online Access: | Get full text |
Tags: |
Add Tag
No Tags, Be the first to tag this record!
|
cited_by | |
---|---|
cites | cdi_FETCH-LOGICAL-c364t-ee192e1bfbeb94421ce4a32bf093c93e2934d4e298895237faeb87cf44f70ec43 |
container_end_page | |
container_issue | |
container_start_page | 1349500 |
container_title | Frontiers in immunology |
container_volume | 15 |
creator | Kannan, Saranya Rutkowski, Joseph M |
description | Lymphatic vessels have been increasingly appreciated in the context of immunology not only as passive conduits for immune and cancer cell transport but also as key in local tissue immunomodulation. Targeting lymphatic vessel growth and potential immune regulation often takes advantage of vascular endothelial growth factor receptor-3 (VEGFR-3) signaling to manipulate lymphatic biology. A receptor tyrosine kinase, VEGFR-3, is highly expressed on lymphatic endothelial cells, and its signaling is key in lymphatic growth, development, and survival and, as a result, often considered to be "lymphatic-specific" in adults. A subset of immune cells, notably of the monocyte-derived lineage, have been identified to express VEGFR-3 in tissues from the lung to the gut and in conditions as varied as cancer and chronic kidney disease. These VEGFR-3+ macrophages are highly chemotactic toward the VEGFR-3 ligands VEGF-C and VEGF-D. VEGFR-3 signaling has also been implicated in dictating the plasticity of these cells from pro-inflammatory to anti-inflammatory phenotypes. Conversely, expression may potentially be transient during monocyte differentiation with unknown effects. Macrophages play critically important and varied roles in the onset and resolution of inflammation, tissue remodeling, and vasculogenesis: targeting lymphatic vessel growth and immunomodulation by manipulating VEGFR-3 signaling may thus impact macrophage biology and their impact on disease pathogenesis. This mini review highlights the studies and pathologies in which VEGFR-3+ macrophages have been specifically identified, as well as the activity and polarization changes that macrophage VEGFR-3 signaling may elicit, and affords some conclusions as to the importance of macrophage VEGFR-3 signaling in disease. |
doi_str_mv | 10.3389/fimmu.2024.1349500 |
format | article |
fullrecord | <record><control><sourceid>proquest_doaj_</sourceid><recordid>TN_cdi_doaj_primary_oai_doaj_org_article_33b5a6891c794962a85dccace18276e4</recordid><sourceformat>XML</sourceformat><sourcesystem>PC</sourcesystem><doaj_id>oai_doaj_org_article_33b5a6891c794962a85dccace18276e4</doaj_id><sourcerecordid>2955264244</sourcerecordid><originalsourceid>FETCH-LOGICAL-c364t-ee192e1bfbeb94421ce4a32bf093c93e2934d4e298895237faeb87cf44f70ec43</originalsourceid><addsrcrecordid>eNpNUctKBDEQDKKoqD_gQeboZdZJd88jehARHwsLgqjXkMl01sg81mT34N-7465iX6rprq6GKiFOZTZBrNSF8123mkAGNJFIKs-yHXEoi4JSBKDdf_2BOInxI1sXKUTM98UBVlRQDnAort7uHu6fU0yin_em9f088X3SGRuGxbuZc7xMXPDcN8kQEjfwuG18ZBP5-ljsOdNGPtnikXi9v3u5fUxnTw_T25tZarGgZcosFbCsXc21IgJpmQxC7TKFViGDQmpoDVWlcsDSGa6r0joiV2ZsCY_EdKPbDOZDL4LvTPjSg_H6ZzCEuTZh6W3LGrHOTVEpaUtFqgBT5Y21xrKsoCx41DrfaC3C8LniuNSdj5bb1vQ8rKIGledQENBIhQ117UWMgd3fa5npMQP9k4EeM9DbDNZHZ1v9Vd1x83fy6zh-A9Q2gI8</addsrcrecordid><sourcetype>Open Website</sourcetype><iscdi>true</iscdi><recordtype>article</recordtype><pqid>2955264244</pqid></control><display><type>article</type><title>VEGFR-3 signaling in macrophages: friend or foe in disease?</title><source>PubMed Central</source><creator>Kannan, Saranya ; Rutkowski, Joseph M</creator><creatorcontrib>Kannan, Saranya ; Rutkowski, Joseph M</creatorcontrib><description>Lymphatic vessels have been increasingly appreciated in the context of immunology not only as passive conduits for immune and cancer cell transport but also as key in local tissue immunomodulation. Targeting lymphatic vessel growth and potential immune regulation often takes advantage of vascular endothelial growth factor receptor-3 (VEGFR-3) signaling to manipulate lymphatic biology. A receptor tyrosine kinase, VEGFR-3, is highly expressed on lymphatic endothelial cells, and its signaling is key in lymphatic growth, development, and survival and, as a result, often considered to be "lymphatic-specific" in adults. A subset of immune cells, notably of the monocyte-derived lineage, have been identified to express VEGFR-3 in tissues from the lung to the gut and in conditions as varied as cancer and chronic kidney disease. These VEGFR-3+ macrophages are highly chemotactic toward the VEGFR-3 ligands VEGF-C and VEGF-D. VEGFR-3 signaling has also been implicated in dictating the plasticity of these cells from pro-inflammatory to anti-inflammatory phenotypes. Conversely, expression may potentially be transient during monocyte differentiation with unknown effects. Macrophages play critically important and varied roles in the onset and resolution of inflammation, tissue remodeling, and vasculogenesis: targeting lymphatic vessel growth and immunomodulation by manipulating VEGFR-3 signaling may thus impact macrophage biology and their impact on disease pathogenesis. This mini review highlights the studies and pathologies in which VEGFR-3+ macrophages have been specifically identified, as well as the activity and polarization changes that macrophage VEGFR-3 signaling may elicit, and affords some conclusions as to the importance of macrophage VEGFR-3 signaling in disease.</description><identifier>ISSN: 1664-3224</identifier><identifier>EISSN: 1664-3224</identifier><identifier>DOI: 10.3389/fimmu.2024.1349500</identifier><identifier>PMID: 38464522</identifier><language>eng</language><publisher>Switzerland: Frontiers Media S.A</publisher><subject>Endothelial Cells - metabolism ; FLT4/VEGFR3 ; lymphangiogenesis ; Lymphangiogenesis - physiology ; M1 macrophage ; M2 macrophage ; Macrophages - metabolism ; monocyte ; Vascular Endothelial Growth Factor A - metabolism ; Vascular Endothelial Growth Factor Receptor-3 - metabolism ; VEGFC/D-VEGFR3/NRP2 axis</subject><ispartof>Frontiers in immunology, 2024, Vol.15, p.1349500</ispartof><rights>Copyright © 2024 Kannan and Rutkowski.</rights><lds50>peer_reviewed</lds50><oa>free_for_read</oa><woscitedreferencessubscribed>false</woscitedreferencessubscribed><cites>FETCH-LOGICAL-c364t-ee192e1bfbeb94421ce4a32bf093c93e2934d4e298895237faeb87cf44f70ec43</cites></display><links><openurl>$$Topenurl_article</openurl><openurlfulltext>$$Topenurlfull_article</openurlfulltext><thumbnail>$$Tsyndetics_thumb_exl</thumbnail><link.rule.ids>314,780,784,4023,27922,27923,27924</link.rule.ids><backlink>$$Uhttps://www.ncbi.nlm.nih.gov/pubmed/38464522$$D View this record in MEDLINE/PubMed$$Hfree_for_read</backlink></links><search><creatorcontrib>Kannan, Saranya</creatorcontrib><creatorcontrib>Rutkowski, Joseph M</creatorcontrib><title>VEGFR-3 signaling in macrophages: friend or foe in disease?</title><title>Frontiers in immunology</title><addtitle>Front Immunol</addtitle><description>Lymphatic vessels have been increasingly appreciated in the context of immunology not only as passive conduits for immune and cancer cell transport but also as key in local tissue immunomodulation. Targeting lymphatic vessel growth and potential immune regulation often takes advantage of vascular endothelial growth factor receptor-3 (VEGFR-3) signaling to manipulate lymphatic biology. A receptor tyrosine kinase, VEGFR-3, is highly expressed on lymphatic endothelial cells, and its signaling is key in lymphatic growth, development, and survival and, as a result, often considered to be "lymphatic-specific" in adults. A subset of immune cells, notably of the monocyte-derived lineage, have been identified to express VEGFR-3 in tissues from the lung to the gut and in conditions as varied as cancer and chronic kidney disease. These VEGFR-3+ macrophages are highly chemotactic toward the VEGFR-3 ligands VEGF-C and VEGF-D. VEGFR-3 signaling has also been implicated in dictating the plasticity of these cells from pro-inflammatory to anti-inflammatory phenotypes. Conversely, expression may potentially be transient during monocyte differentiation with unknown effects. Macrophages play critically important and varied roles in the onset and resolution of inflammation, tissue remodeling, and vasculogenesis: targeting lymphatic vessel growth and immunomodulation by manipulating VEGFR-3 signaling may thus impact macrophage biology and their impact on disease pathogenesis. This mini review highlights the studies and pathologies in which VEGFR-3+ macrophages have been specifically identified, as well as the activity and polarization changes that macrophage VEGFR-3 signaling may elicit, and affords some conclusions as to the importance of macrophage VEGFR-3 signaling in disease.</description><subject>Endothelial Cells - metabolism</subject><subject>FLT4/VEGFR3</subject><subject>lymphangiogenesis</subject><subject>Lymphangiogenesis - physiology</subject><subject>M1 macrophage</subject><subject>M2 macrophage</subject><subject>Macrophages - metabolism</subject><subject>monocyte</subject><subject>Vascular Endothelial Growth Factor A - metabolism</subject><subject>Vascular Endothelial Growth Factor Receptor-3 - metabolism</subject><subject>VEGFC/D-VEGFR3/NRP2 axis</subject><issn>1664-3224</issn><issn>1664-3224</issn><fulltext>true</fulltext><rsrctype>article</rsrctype><creationdate>2024</creationdate><recordtype>article</recordtype><sourceid>DOA</sourceid><recordid>eNpNUctKBDEQDKKoqD_gQeboZdZJd88jehARHwsLgqjXkMl01sg81mT34N-7465iX6rprq6GKiFOZTZBrNSF8123mkAGNJFIKs-yHXEoi4JSBKDdf_2BOInxI1sXKUTM98UBVlRQDnAort7uHu6fU0yin_em9f088X3SGRuGxbuZc7xMXPDcN8kQEjfwuG18ZBP5-ljsOdNGPtnikXi9v3u5fUxnTw_T25tZarGgZcosFbCsXc21IgJpmQxC7TKFViGDQmpoDVWlcsDSGa6r0joiV2ZsCY_EdKPbDOZDL4LvTPjSg_H6ZzCEuTZh6W3LGrHOTVEpaUtFqgBT5Y21xrKsoCx41DrfaC3C8LniuNSdj5bb1vQ8rKIGledQENBIhQ117UWMgd3fa5npMQP9k4EeM9DbDNZHZ1v9Vd1x83fy6zh-A9Q2gI8</recordid><startdate>2024</startdate><enddate>2024</enddate><creator>Kannan, Saranya</creator><creator>Rutkowski, Joseph M</creator><general>Frontiers Media S.A</general><scope>CGR</scope><scope>CUY</scope><scope>CVF</scope><scope>ECM</scope><scope>EIF</scope><scope>NPM</scope><scope>AAYXX</scope><scope>CITATION</scope><scope>7X8</scope><scope>DOA</scope></search><sort><creationdate>2024</creationdate><title>VEGFR-3 signaling in macrophages: friend or foe in disease?</title><author>Kannan, Saranya ; Rutkowski, Joseph M</author></sort><facets><frbrtype>5</frbrtype><frbrgroupid>cdi_FETCH-LOGICAL-c364t-ee192e1bfbeb94421ce4a32bf093c93e2934d4e298895237faeb87cf44f70ec43</frbrgroupid><rsrctype>articles</rsrctype><prefilter>articles</prefilter><language>eng</language><creationdate>2024</creationdate><topic>Endothelial Cells - metabolism</topic><topic>FLT4/VEGFR3</topic><topic>lymphangiogenesis</topic><topic>Lymphangiogenesis - physiology</topic><topic>M1 macrophage</topic><topic>M2 macrophage</topic><topic>Macrophages - metabolism</topic><topic>monocyte</topic><topic>Vascular Endothelial Growth Factor A - metabolism</topic><topic>Vascular Endothelial Growth Factor Receptor-3 - metabolism</topic><topic>VEGFC/D-VEGFR3/NRP2 axis</topic><toplevel>peer_reviewed</toplevel><toplevel>online_resources</toplevel><creatorcontrib>Kannan, Saranya</creatorcontrib><creatorcontrib>Rutkowski, Joseph M</creatorcontrib><collection>Medline</collection><collection>MEDLINE</collection><collection>MEDLINE (Ovid)</collection><collection>MEDLINE</collection><collection>MEDLINE</collection><collection>PubMed</collection><collection>CrossRef</collection><collection>MEDLINE - Academic</collection><collection>DOAJ Directory of Open Access Journals</collection><jtitle>Frontiers in immunology</jtitle></facets><delivery><delcategory>Remote Search Resource</delcategory><fulltext>fulltext</fulltext></delivery><addata><au>Kannan, Saranya</au><au>Rutkowski, Joseph M</au><format>journal</format><genre>article</genre><ristype>JOUR</ristype><atitle>VEGFR-3 signaling in macrophages: friend or foe in disease?</atitle><jtitle>Frontiers in immunology</jtitle><addtitle>Front Immunol</addtitle><date>2024</date><risdate>2024</risdate><volume>15</volume><spage>1349500</spage><pages>1349500-</pages><issn>1664-3224</issn><eissn>1664-3224</eissn><abstract>Lymphatic vessels have been increasingly appreciated in the context of immunology not only as passive conduits for immune and cancer cell transport but also as key in local tissue immunomodulation. Targeting lymphatic vessel growth and potential immune regulation often takes advantage of vascular endothelial growth factor receptor-3 (VEGFR-3) signaling to manipulate lymphatic biology. A receptor tyrosine kinase, VEGFR-3, is highly expressed on lymphatic endothelial cells, and its signaling is key in lymphatic growth, development, and survival and, as a result, often considered to be "lymphatic-specific" in adults. A subset of immune cells, notably of the monocyte-derived lineage, have been identified to express VEGFR-3 in tissues from the lung to the gut and in conditions as varied as cancer and chronic kidney disease. These VEGFR-3+ macrophages are highly chemotactic toward the VEGFR-3 ligands VEGF-C and VEGF-D. VEGFR-3 signaling has also been implicated in dictating the plasticity of these cells from pro-inflammatory to anti-inflammatory phenotypes. Conversely, expression may potentially be transient during monocyte differentiation with unknown effects. Macrophages play critically important and varied roles in the onset and resolution of inflammation, tissue remodeling, and vasculogenesis: targeting lymphatic vessel growth and immunomodulation by manipulating VEGFR-3 signaling may thus impact macrophage biology and their impact on disease pathogenesis. This mini review highlights the studies and pathologies in which VEGFR-3+ macrophages have been specifically identified, as well as the activity and polarization changes that macrophage VEGFR-3 signaling may elicit, and affords some conclusions as to the importance of macrophage VEGFR-3 signaling in disease.</abstract><cop>Switzerland</cop><pub>Frontiers Media S.A</pub><pmid>38464522</pmid><doi>10.3389/fimmu.2024.1349500</doi><oa>free_for_read</oa></addata></record> |
fulltext | fulltext |
identifier | ISSN: 1664-3224 |
ispartof | Frontiers in immunology, 2024, Vol.15, p.1349500 |
issn | 1664-3224 1664-3224 |
language | eng |
recordid | cdi_doaj_primary_oai_doaj_org_article_33b5a6891c794962a85dccace18276e4 |
source | PubMed Central |
subjects | Endothelial Cells - metabolism FLT4/VEGFR3 lymphangiogenesis Lymphangiogenesis - physiology M1 macrophage M2 macrophage Macrophages - metabolism monocyte Vascular Endothelial Growth Factor A - metabolism Vascular Endothelial Growth Factor Receptor-3 - metabolism VEGFC/D-VEGFR3/NRP2 axis |
title | VEGFR-3 signaling in macrophages: friend or foe in disease? |
url | http://sfxeu10.hosted.exlibrisgroup.com/loughborough?ctx_ver=Z39.88-2004&ctx_enc=info:ofi/enc:UTF-8&ctx_tim=2025-01-08T17%3A39%3A26IST&url_ver=Z39.88-2004&url_ctx_fmt=infofi/fmt:kev:mtx:ctx&rfr_id=info:sid/primo.exlibrisgroup.com:primo3-Article-proquest_doaj_&rft_val_fmt=info:ofi/fmt:kev:mtx:journal&rft.genre=article&rft.atitle=VEGFR-3%20signaling%20in%20macrophages:%20friend%20or%20foe%20in%20disease?&rft.jtitle=Frontiers%20in%20immunology&rft.au=Kannan,%20Saranya&rft.date=2024&rft.volume=15&rft.spage=1349500&rft.pages=1349500-&rft.issn=1664-3224&rft.eissn=1664-3224&rft_id=info:doi/10.3389/fimmu.2024.1349500&rft_dat=%3Cproquest_doaj_%3E2955264244%3C/proquest_doaj_%3E%3Cgrp_id%3Ecdi_FETCH-LOGICAL-c364t-ee192e1bfbeb94421ce4a32bf093c93e2934d4e298895237faeb87cf44f70ec43%3C/grp_id%3E%3Coa%3E%3C/oa%3E%3Curl%3E%3C/url%3E&rft_id=info:oai/&rft_pqid=2955264244&rft_id=info:pmid/38464522&rfr_iscdi=true |